Novan — Investor Presentation (October 2017)
33 slides from Novan's investor presentation, Oct 23, 2017
Slide 1: Corporate Overview
Corporate Overview October 23, 2017 Exhibit 99.1
Slide 2: Forward Looking Statements
This presentation includes forward-looking statements that reflect our current views with respect to, among other things, our plans to develop and commercialize our product candidates, including our interpretation of preclinical studies and the success and timing of our product development activitie
Slide 3: Experienced Leadership
Experienced Leadership Nate Stasko, PhD President and Chief Scientific Officer Paula Brown Stafford Chief Development Officer Stan Hollenbach, JD Senior VP, Research and Nonclinical Development Kevin Barber, PhD, RAC VP, Regulatory Affairs Tomoko Maeda-Chubachi. MD VP, Medical Dermatology Lawrence E
Slide 4: Nitric Oxide Mechanisms of Action
Nitric Oxide Mechanisms of Action Nobel Prize in Medicine (1998) >100,000 peer reviewed manuscripts Broad Spectrum Antimicrobial Antiviral Antibacterial Antifungal Immunomodulatory Agent Decreases key inflammatory cytokines Modulates cellular trafficking Inhibits T cell proliferation Results in NO-d
Slide 5: Scientific Foundation: Nitric Oxide Platform
Scientific Foundation: Nitric Oxide Platform NVN1000 Nitric Oxide Proprietary chemistry that stores large amounts of nitric oxide in solid form Macromolecular NCEs Core Drug Candidates Indication specific formulations with differentiated nitric oxide release rates Formulation Science Nitricil Techno
Slide 6: Potential Therapeutic Applications of Nitric Oxide
Potential Therapeutic Applications of Nitric Oxide Androgenetic alopecia Bromhidrosis Hyperseborrhea Medical Aesthetics Rosacea Psoriasis Atopic dermatitis Inflammatory Skin Diseases Warts (HPV) Oncoviruses Molluscum (Pox) Viral Infections Multi-factorial Diseases Acne vulgaris Seborrheic dermatitis
Slide 7: Potential Therapeutic Applications of Nitric Oxide
Potential Therapeutic Applications of Nitric Oxide Androgenetic alopecia Bromhidrosis Hyperseborrhea Medical Aesthetics Rosacea Psoriasis Atopic dermatitis Inflammatory Skin Diseases Warts (HPV) Oncoviruses Molluscum (Pox) Viral Infections Multi-factorial Diseases Acne vulgaris Seborrheic dermatitis
Slide 8: Core Development Pipeline
Core Development Pipeline Product Candidates Indication Target Preclinical Phase 1 Phase 2 Phase 3 SB206 Genital Warts HPV 6&11 Molluscum Poxvirus HPV-Associated STIs HPV 16&18 NVN3100 Anal Neoplasia (HGAIN) HPV 16&18 Cervical Neoplasia (CIN 2/3) HPV 16&18 SB414 Psoriasis IL-1, IL-17 Atopic Dermatit
Slide 9: Research Collaborations
Research Collaborations Virology Immunology Thomas Broker, PhD Louise Chow, PhD Professors of Biochemistry and Molecular Genetics Richard Gallo, MD, PhD Chief of Division for Dermatology at University of California, San Diego School of Medicine Neil Christensen, PhD Professor of Pathology, and Micro
Slide 10: SB206 – Antiviral Program
SB206 – Antiviral Program Approximately 20% of human cancers worldwide are caused by oncoviruses
Slide 11: Human Papillomavirus (HPV)
Human Papillomavirus (HPV) Cervical Neoplasias Cervical Cancer 10,6003 Anal Neoplasias Oropharyngeal Cancer 11,6003 Common Warts Genital Warts Plantar Warts DNA virus with >100 subtypes, low- and high-risk strains based on their cancer-causing potential1 During 2013-2014, 22.7% of total US adult pop
Slide 12: Papillomavirus Proof-of-Concept Data
Papillomavirus Proof-of-Concept Data HPV-18 Viral Replication in Human Raft Cultures Untreated Control qPCR analysis of HPV-18 viral copy number BrdU stained cells are indicative of rapidly dividing nuclei and pervasive viral infection throughout epithelium 1.5 mg/mL NVN1000 NVN1000 All high-risk HP
Slide 13: Papillomavirus Proof-of-Concept Data
Phase 2 study: statistically significant clearance of baseline warts (QD dosing)2 Secondary Endpoint – Proportion of subjects with complete clearance of all warts was 30% for 12% SB206 QD and 4% for Vehicle QD (p< 0.02) Papillomavirus Proof-of-Concept Data Primary Endpoint - Complete Clearance of Ba
Slide 14: SB206 – Planned Expansion of Clinical Development Program
SB206 – Planned Expansion of Clinical Development Program SB206* End of Phase 2 Meeting with FDA Max Use PK Trial Phase 3 Pivotals Long Term Safety Phase 2 Ascending Dose Trial Phase 1b POC for topical eradication of HPV 16 & 18 STIs 12% SB206 vs. Vehicle assessing viral load, HPV genotyping followi
Slide 15: SB206 as a Potential Treatment for Molluscum Contagiosum
SB206 as a Potential Treatment for Molluscum Contagiosum Key Milestones Background There are no FDA-approved treatments indicated for molluscum contagiosum Molluscum is a contagious skin infection caused by the molluscipoxvirus Affects ~6M sufferers in US, mostly children Greatest incidence in child
Slide 16: Study of Topical Nitric Oxide in the Treatment of Molluscum
Phase 2 Study of Topical Nitric Oxide in the Treatment of Molluscum Results 12.9% 33.3% 48.4% 29.0% Number of Patients with Complete Clearance Complete Clearance of Baseline Lesions (ITT) 16.7% 22.6% In-licensed Anti-viral Topical Nitric Oxide Know How to De-risk SB206 Development At week 4, high-do
Slide 17: SB206 Planned Phase 2 Molluscum Trial
SB206 Planned Phase 2 Molluscum Trial Strawman of Ascending Dose Trial Design Randomized 3:1 (N=64 per cohort) T T T NT NT NT T or NT T: Tolerable NT: Not Tolerable 4% BID Vehicle 8% BID Vehicle 4% QD Vehicle 4% TIW Vehicle 12% BID Vehicle 4% QD Vehicle 12% QD Vehicle 8% QD Vehicle Primary Endpoint
Slide 18: NVN3100 Aims to Address Unmet Need for High Risk Neoplasias
NVN3100 Aims to Address Unmet Need for High Risk Neoplasias Disease Progression and Annual Incidence of HPV 16 & 18+ CIN 2+ Current Treatments Fail to Treat Underlying HPV Infection Given current treatment options physicians often take a “watch and wait” approach for the more common LSIL (low grade
Slide 19: SB414 Inflammatory Skin Disease Program
SB414 Inflammatory Skin Disease Program
Slide 20: Psoriasis: IL-17 is a Proximal Target for Keratinocyte Effect
Psoriasis: IL-17 is a Proximal Target for Keratinocyte Effect Lynde, C et al., J Am. Acad. Dermatol. 2014. 71:141-150 Ixekizumab @ Week 12: PASI 75 – 90% PASI 90 - 71% (2016) Ustekinumab (45 mg) @ Week 12: PASI 75 – 67% PASI 90 – 42% (2009) Etanercept @ Week 12: PASI 75 – 49% (1998)
Slide 21: NLRP3 Inflammasome and Nitric Oxide's Multiple Targets
NLRP3 Inflammasome and Nitric Oxide’s Multiple Targets Mishra B et al. Nature Immunology. 2013;14:52-60. Niedbala W et al. Proc Natl Acad Sci USA. 2011;108(22):9220-9225 Niedbala W et al. J Immunol. 2013;191(1):164-170. Binding of IL-17A to its receptor stimulates NFκB and perpetuates pro-inflammato
Slide 22: Psoriasis Market and SB414 Value Proposition
Psoriasis Market and SB414 Value Proposition Market and Disease Overview The total psoriasis market is valued at $5.4Bn with a forecasted growth to $9.1Bn in 20251 Psoriasis market is populated by a number of new entrants at the “severe” end of the disease spectrum IL-17 products are expected to acc
Slide 23: SB414 Topical Cream as a Potential Treatment for Psoriasis
SB414 Topical Cream as a Potential Treatment for Psoriasis SB414 Phase 1b PK/PD Trial SB414 Mechanism of Action Evaluation of systemic exposure via pharmacokinetic assessments on Day 28 Assessment of IL-17A, IL-17F, IL-23 and other biomarkers Immunohistochemistry of tissue biopsies Assessments of sa
Slide 24: Evidence of IL-17 Pathway Activation in Inflammatory Skin Disorders
Evidence of IL-17 Pathway Activation in Inflammatory Skin Disorders Th, T helper cell; Tc, IL-17-producing CD8+ T cell; Y, yes; L, likely, but some conflicting results; C, conflicting results. Circulation Skin Developmental Validation IL-17 in serum/ plasma Th17 cells Tc17 cells Th17/IL-17 levels re
Slide 25: Two pathways for a nitric oxide-based topical to target IL-4 and IL-13
Two pathways for a nitric oxide-based topical to target decreases in IL-4 and IL-13 locally in AD skin Skin barrier defects and bacterial dysbiosis trigger chronic inflammation Entry of S. aureus into skin of filaggrin-deficient mice results in upregulation of IL-4 and IL-132 NLRP3 drives Th2 differ
Slide 26: SB414 Topical Cream as a Potential Treatment for Atopic Dermatitis
SB414 Topical Cream as a Potential Treatment for Atopic Dermatitis Mechanism of Action Key Milestones Phase 1b PK/PD Trial Targeted Initiation – 4Q 2017 TLRs from Phase 1b Trial anticipated – 3Q 2018 Evaluation of systemic exposure via PK assessments of NVN1000 on Day 1 and Day 14 Assessment of IL-4
Slide 27: Upcoming Clinical Milestones: Proposed Activity & Events
Upcoming Clinical Milestones: Proposed Activity & Events SB206 EGW SB206 Molluscum SB414 Psoriasis 4Q 2017 1H 2018 SB414 Atopic Dermatitis Initiate Phase 2 Conduct Max Use PK Trial Initiate Phase 1b Initiate Phase 1b Phase 1b TLRs SB206 HPV 16 & 18 NVN3100 HPV – High-Risk Neoplasias Initiate Phase 1
Slide 28: Unlocking Value Through Strategic Transactions
Unlocking Value Through Strategic Transactions Multi-factorial* Antifungal * Includes anti-inflammatory and antibacterial activity – p. acnes in the case of SB204 for the treatment of acne. Product Candidates Indication Target Preclinical Phase 1 Phase 2 Phase 3 SB204 Acne P acnes, IL-1, IL-17 SB208
Slide 29: SB204 Acne Program
$B204 Acne Program 2 novan
Slide 30: SB204 Guidance Meeting with FDA
SB204 Guidance Meeting with FDA Additional Data Shared with FDA: Long-term safety trial results (NI-AC303) showing sustained treatment benefit Analyses in relevant sub-populations (adolescents, severe subjects only) Mechanism of action data showing effect of SB204 on IL-1b in ex vivo human skin mode
Slide 31: Acne Path Forward
Acne Path Forward Goal: To complete a Phase 3 pivotal trial in moderate-to-severe acne patients for the purposes of replication and interpretation of clinical trial findings Potential Partnership Models: Licensing/Collaborative Partnerships Discussions with strategic partners (corporates) ongoing Bo
Slide 32: Key Takeaways
Key Takeaways Approximately 20% of human cancers worldwide are caused by oncoviruses, which will be a focus area of Novan going forward Antiviral Proposed Milestones in 2018 SB206 Phase 2 TLRs in molluscum contagiosum – 4Q 2018 SB206 Phase 1b TLRs in HPV-associated sexually transmitted infections –
Slide 33: Summary of Intellectual Property Portfolio
Summary of Intellectual Property Portfolio Covered Patent Life Issued Patents (Pending Applications) NitricilTM Technology Composition of Matter Family of Compounds – 8,282,967 NVN1000 Composition – 8,956,658 Method of Manufacture to 2026 to 2032 US, Japan, Australia (US, Canada, EUR) US, China, Swi